 |
Top 80 medical and healthcare startups in France
Oct 12, 2024 | By Jason Kwon | 16 |
2
Funding: $854.1M
Valneva is a pharmaceutical company focused on the prevention of infectious diseases with significant unmet medical need.
Valneva is a pharmaceutical company focused on the prevention of infectious diseases with significant unmet medical need.
3
Funding: €666M
Alan wants to make health insurance as simple as subscribing to a software-as-a-service product. It starts with clear pricing and transparent reimbursement policies.
Alan wants to make health insurance as simple as subscribing to a software-as-a-service product. It starts with clear pricing and transparent reimbursement policies.
4
Funding: €81M
UroMems ambition is to offer to the patients suffering from severe urinary incontinence a simple and efficient innovative solution. UroMems is currently developing an active implantable medical device which compensates for sphincter insufficiency.
UroMems ambition is to offer to the patients suffering from severe urinary incontinence a simple and efficient innovative solution. UroMems is currently developing an active implantable medical device which compensates for sphincter insufficiency.
5
Funding: $816.5M
Doctolib is an online and mobile booking platform that helps to find a specialist doctor nearby and make an appointment.
Doctolib is an online and mobile booking platform that helps to find a specialist doctor nearby and make an appointment.
6
Funding: $388.2M
Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer.
Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer.
7
Funding: $356.6M
Pharnext is a biopharmaceutical company engaged in the development of treatments for severe neurological diseases.
Pharnext is a biopharmaceutical company engaged in the development of treatments for severe neurological diseases.
8
Funding: $304.1M
OWKIN is the AI startup that uses machine learning to augment medical and biology research. Our proprietary platform, OWKIN Socrates, uses machine learning technology to integrate biomedical images, genomics and clinical data to discover biomarkers and mechanisms associated with diseases and treatment outcomes.
OWKIN is the AI startup that uses machine learning to augment medical and biology research. Our proprietary platform, OWKIN Socrates, uses machine learning technology to integrate biomedical images, genomics and clinical data to discover biomarkers and mechanisms associated with diseases and treatment outcomes.
9
Funding: $263.9M
We are a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. To address these therapeutic areas, we leverage our integrated development platform by combining a gene therapy-based approach with our core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics.
We are a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. To address these therapeutic areas, we leverage our integrated development platform by combining a gene therapy-based approach with our core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics.
10
Funding: €238.1M
The mission of every team member at Carmat is to contribute to the development of innovative artificial organs – the artificial heart today, tomorrow other vital organs – to treat millions of patients affected by advanced disease of these organs and to restore their normal life.
The mission of every team member at Carmat is to contribute to the development of innovative artificial organs – the artificial heart today, tomorrow other vital organs – to treat millions of patients affected by advanced disease of these organs and to restore their normal life.
11
Funding: $210M
Tissium invents the next generation of synthetic polymers for tissue reconstruction
Tissium invents the next generation of synthetic polymers for tissue reconstruction
12
Funding: €175.8M
Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer (OncoMimics™ peptides). Enterome’s pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system.
Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer (OncoMimics™ peptides). Enterome’s pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system.
13
Funding: €172.9M
ImCheck Therapeutics is a privately-held French biotech company pioneering the next generation of immune checkpoint modulators.
ImCheck Therapeutics is a privately-held French biotech company pioneering the next generation of immune checkpoint modulators.
14
Funding: $179.8M
Inventiva is a clinical stage biopharmaceutical company with an expertise in fibrosis, oncology and orphan diseases. We are focussing on diseases with a high unmet medical need where either no treatments are available, such as NASH and Systemic Sclerosis, or the current standard of care leaves important manifestations of the diseases unaffected, as it is the case in many lysosomal storage diseases.
Inventiva is a clinical stage biopharmaceutical company with an expertise in fibrosis, oncology and orphan diseases. We are focussing on diseases with a high unmet medical need where either no treatments are available, such as NASH and Systemic Sclerosis, or the current standard of care leaves important manifestations of the diseases unaffected, as it is the case in many lysosomal storage diseases.
15
Funding: $179.5M
HiFiBiO Therapeutics is biotherapeutics company mobilizing the human immune system to combat disease. We integrate deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. We also aspire to benefit patients through open-innovation partnerships with industry and academia.
HiFiBiO Therapeutics is biotherapeutics company mobilizing the human immune system to combat disease. We integrate deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. We also aspire to benefit patients through open-innovation partnerships with industry and academia.
16
Funding: €132.3M
Diabeloop is a medical device company for diabetes and closed-loop system.
Diabeloop is a medical device company for diabetes and closed-loop system.
17
Funding: $127.6M
SparingVision is a biotechnology company focused on the discovering and development of an innovative, therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa.
SparingVision is a biotechnology company focused on the discovering and development of an innovative, therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa.
18
Funding: $112.2M
Genfit SA, a biopharmaceutical engages in the research and development of drugs for the prevention and treatment.
Genfit SA, a biopharmaceutical engages in the research and development of drugs for the prevention and treatment.
19
Funding: €103.5M
ENYO Pharma is a clinical stage Biotech with a unique drug discovery engine inspired by viruses. In particular it develops drug for Chronic Hepatitis B.
ENYO Pharma is a clinical stage Biotech with a unique drug discovery engine inspired by viruses. In particular it develops drug for Chronic Hepatitis B.
